Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report sent to investors on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

BCLI opened at $1.55 on Tuesday. The company has a market capitalization of $8.84 million, a price-to-earnings ratio of -0.32 and a beta of 0.74. Brainstorm Cell Therapeutics has a 1-year low of $1.05 and a 1-year high of $11.89. The business has a 50 day moving average price of $1.81 and a two-hundred day moving average price of $2.16.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.